Serotonin-mediated cyclic AMP inhibitory pathway in platelets of patients affected by panic disorder

Neuropsychobiology

Volumn 50, Issue 1, 2004, Pages 28-36

  Dell'Osso, Liliana ^a   Carmassi, Claudia ^a   Palego, Lionella ^a   Trincavelli, Maria Letizia ^a   Tuscano, Daniela ^a   Montali, Marina ^a   Sbrana, Simone ^a   Ciapparelli, Antonio ^a   Lucacchini, Antonio ^a   Cassano, Giovanni Battista ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adenylyl cyclase activity; G protein coupling; Human platelets; Panic disorder; Paroxetine; Serotonergic system

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PAROXETINE; SEROTONIN; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; MALE; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE;

ADULT; BLOOD PLATELETS; CASE-CONTROL STUDIES; CYCLIC AMP; HUMANS; MALE; PANIC DISORDER; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 2642567556     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077938     Document Type: Article

References (48)

1. Charney DS, Heninger GR, Brier A: Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984;41:751-763.
2. Graeff F: Role of 5-HT in defensive behavior and anxiety. Rev Neurosci 1993;4:181-211.
3. Zacharko RM, Koszycki D, Mendella PD, Bradwejn J: Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: multiple transmitter interaction and neuropeptide colocalization. Progr Neurobiol 1995;45:371-423.
4. Deakin JF: Role of serotonin in panic, depression and anxiety disorders. Int Clin Psychopharmacol 1998;13:S1-S5.
5. Braune S, Albus M, Frohler M, Hohn T, Scheibe G: Psychophysiological and biochemical changes in patients with panic attacks in a defined situational arousal. Eur Arch Psych Clin Neurosci 1994;244:86-92.
6. Taylor S, Koch WJ: Anxiety sensitivity and depression: How are they related? Abnorm Psychol 1996;105:474-479.
7. Lerer B, Ebstein RP, Shestatsky M, Shemesh Z, Greenberg D: Cyclic AMP signal transduction in posttraumatic stress disorder. Am J Psychiatry 1987;144:1324-1327.
8. Marcourakis T, Gorenstein C, Brandao de Almeida Prado E, Ramos RT, Glezer I, Bernardes CS, Kawamoto EM, Scavone C: Panic disorder patients have reduced cyclic AMP in platelets. J Psychiatr Res 2002;36:105-110.
9. 2-receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. Neuropsychopharmacology 1999;20:162-176.
10. Stein MB, Chen G, Potter WZ, Manjii H: G-protein level quantification in platelets and leukocytes from patients with panic disorder. Neuropharmacology 1996;15:181-186.
11. 1A receptor-effector system responsiveness in panic disorder. Psychopharmacology 1992;106:111-117.
12. 3H-paroxetine binding in untreated panic disorder patients. Life Sci 1999;25:2735-2741.
13. McIntyre IM, Judd FK, Burrows GD, Norman TR: Serotonin in panic disorder: Platelet uptake and concentration. Int Clin Psychopharmacol 1989;4:1-6.
14. Starkman MN, Cameron OG, Nesse RM, Zelnik T: Peripheral catecholamine levels and the symptoms of anxiety: Studies in patients with and without pheochromocytoma. Psychosom Med 1990;52:129-142.
15. Stein MB, Tancer ME, Uhde TW: Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects. Arch Gen Psychiatry 1992;49:311-317.
16. Bremner JD, Krystal JH, Southwick SM, Charney DS: Noradrenergic mechanisms in stress and anxiety. II. Clinical studies. Synapse 1996;23:39-51.
17. Coplan JD, Pine DS, Papp LA, Gorman JM: A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin- releasing factor function in anxiety and affective disorders: The reduced growth hormone response to clonidine. Psychopharmacol Bull 1997;33:193-204.
18. Gurguis GN, Uhde TW: The relationship between plasma MHPG and NE: Employing regression models in estimating centrally derived MHPG and peripheral NE turnover rate in panic disorder. J Psychiatr Rev 1998;32:11-17.
19. Heninger GR, Charney DS, Price LH: Noradrenergic and serotonergic receptor system function in panic disorder and depression. Acta Psychiatr Scand Suppl 1988;341:138-150.
20. Masi G, Toni C, Mucci M, Millepiedi S, Mata B, Perugi G: Paroxetine in child and adolescent outpatients with panic disorder. J Child Adolesc Psychopharmacol 2001;11:151-157.
21. Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L: A comparison of citalopram and paroxetine in the treatment of panic disorder: A randomized, single-blind study. Pharmacopsychiatry 2001;34:85-90.
22. Roy-Byrne PP, Clary CM, Miceli RJ, Colucci SV, Xu Y, Grudzinski AN: The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. J Clin Psychiatry 2001;62:678-682.
23. Brauer HR, Nowicki PW, Catalano G, Catalano MC: Panic attacks associated with citalopram. South Med J 2002;95:1088-1089.
24. Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ: A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry 2002;63:772-777.
25. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL: Paroxetine: An update of its use in psychiatric disorders in adults. Drugs 2002;62:655-703.
26. 1A agonists measured with the forced swim test. Psychopharmacology (Berl) 1990;101:497-504.
27. Broocks A, Bandelow B, George A, Jestrabeck C, Opitz M, Bartmann U, Gleiter CH, Meineke I, Roed IS, Ruther E, Hajak G: Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 2000;15:153-161.
28. Rickels K: Buspirone in clinical practice. J Clin Psychiatry 1990;51(suppl):51-54.
29. Cadieux RJ: Azapirones: An alternative to benzodiazepines for anxiety. Am Fam Physician 1996;53:2349-2353.
30. 1A receptor function in brain following agonist or antidepressant administration. Life Sci 2003;72:1665-1682.
31. Stahl SM: Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacol Bull 1985;21:663-671.
32. Lingjærde O: Blood platelets as a model system for studying serotonergic dysfunction and effects of antidepressants. Pharmacol Toxicol 1990;66:61-68.
33. American Psychiatry Association, Committee on Nomenclature & Statistics. Diagnostic and Statistical Manual for Mental Disorders, ed 4. Washington, American Psychiatry Press, 1994.
34. Dell'Osso L, Armani A, Rucci P, Frank E, Fagiolini A, Corretti G, Shear MK, Grochocinski VJ, Maser JD, Endicott J, Cassano GB: Measuring mood spectrum: Comparison of interview (SCI-MOODS) and self-report (MOODS-SR) instruments. Compr Psychiatry 2002;43:69-73.
35. Shear MK, Frank E, Rucci P, Fagiolini A, Grochocinski VJ, Houck P, Cassano GB, Kupfer DJ, Endicott J, Maser JD, Mauri M, Banti S: Panic-agoraphobic spectrum: Reliability and validity of assessment instruments. J Psychiatr Res 2001;35:59-66.
36. Guy W: ECDEU Assessment Manual for Psychopharmacology, ed 2. Washington, US Government Printing Office, 1976.
37. Salomon YV: Adenylate cyclase assay; in Brooker G, Greengard P, Robinson GA (eds): Advances in Cyclic Nucleotide Research. New York, Raven Press, 1979, vol 10, pp 35-55.
38. Johnson RA, Alvarez R, Salomon YV: Determination of adenylyl cyclase catalytic activity using single and double column procedures. Methods Enzymol 1994;238:31-56.
39. Peterson GL: Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Anal Biochem 1979;100:201-220.
40. 35S]GTPγS binding to guanine-nucleotide-binding-proteins in human platelet membranes. Life Sci 1999;64:1403-1413.
41. 35S]GTPγS binding in rat brain: Absence of regional differences in coupling efficiency. J Pharmacol Exp Ther 2000;292:684-691.
42. 1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacology 1997;36:451-459.
43. 1A receptor-mediated activity. Biochem Pharmacol 1994;48:1677-1682.
44. Newman ME: Serotonin inhibits adenylate cyclase in human platelet membranes. Eur J Pharmacol 1992;226:281-285.
45. Newman ME, Lerer B, Lichenberg P, Shapira B: Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment: Relation to serotonergic function. Psychopharmacology 1992;109:231-234.
46. 1A receptor: G protein coupling and signalling pathways. Br J Pharmacol 1999;127:1751-1764.
47. 1A receptor expressed in Sf9 insect cells. Biochemistry 1995;34:11954-11962.
48. 1A receptor. J Biol Chem 1991;266:14747-14753.